Anat Galor, MD, MSPH, presented data from the Oculis Phase 2b RELIEF trial that looked at the effects of licaminlimab in patients with signs of DED, and the influence of a genetic marker, the CC genotype of single nucleotide polymorphism rs1800693 in the TNFα receptor gene.
OcuSciences, Inc. announced at ARVO that the FDA has granted marketing clearance for its flagship device, the OcuMet Beacon, a confocal scanning ophthalmoscope designed for infrared and autofluorescence imaging of the retina.
